Deal Watch: OrsoBio Reveals Its Metabolic Health Focus With Four Licensing Pacts

03 Nov 2022

California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.

Deal Watch 2021 — • Source: Shutterstock

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.

Metabolic disease-focused OrsoBio, Inc. made a splash on 2 November by unveiling licensing agreements with three biopharmas as well...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Deal Watch: Lilly Teams With GPCR-Focused Superluminal In Cardiometabolic Disease

14 Aug 2025

• By Joseph Haas

Plus deals involving Basilea/Venatorx, CorMedix/Melinta, SERB/Y-mAbs, XOMA/Lava, XOMA/Hillevax, MaxCyte/Adicet/Anocca and Bausch Health/DURECT.

Asia Deal Watch: Lupin Picks Sandoz To Market Lucentis Biosimilar In Parts Of EU And Asia

13 Aug 2025

• By Joseph Haas, Sushmita Panda, Xu Hu, Vibha Ravi, and Manas Mishra

Also deals involving Xspray/Handa, Fosun/Expedition, Kaken/Astria, Orchid/Allecra, Sanofi/Visirna, KKR/Healthcare Royalty Partners, Viridian/Kissei, Sandoz/Evotec, Dx&Vx, Dr. Falk/Allianthera, Madrigal/CSPC and Lilly/LTZ.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

25 Jul 2025

• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

16 Jul 2025

• By Joseph Haas, Manas Mishra, and Sushmita Panda

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

12 Aug 2025

• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream

07 Aug 2025

• By Manas Mishra

Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.

Verona’s COPD Launch Success Sealed Merck Buyout Interest